Rationale and Design of the Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial: A Prospective, Multi-Center, Double-Blind, Randomized Controlled Trial Evaluating Reductions in Postoperative Bleeding with Intraoperative Removal of Ticagrelor by the Drugsorb™-Atr Device in Patients Undergoing Cardiothoracic Surgery Within 48 Hours from Last Ticagrelor Dose.
American heart journal/The American heart journal（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined